Tekla Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Tekla Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,029	Closed	-$3.1M	–	188
2021 Q2	$3.1M	Hold	12,029	–	–	0.1%	142
2021 Q1	$3.61M	Hold	12,029	–	–	0.12%	138
2020 Q4	$3.07M	Sell	12,029 -5,510	-31%	-$1.42M	0.11%	143
2020 Q3	$4.36M	Hold	17,539	–	–	0.16%	112
2020 Q2	$6.09M	Hold	17,539	–	–	0.23%	89
2020 Q1	$4.7M	Sell	17,539 -1,373	-7%	-$425K	0.21%	89
2019 Q4	$6.12M	Hold	18,912	–	–	0.23%	91
2019 Q3	$5.17M	Hold	18,912	–	–	0.23%	80
2019 Q2	$10.1M	Hold	18,912	–	–	0.41%	57
2019 Q1	$9.53M	Buy	18,912 +12,620	+201%	+$7.48M	0.39%	55
2018 Q4	$3.1M	Sell	6,292 -7,873	-56%	-$4.75M	0.13%	106
2018 Q3	$13M	Buy	14,165 +1,580	+13%	+$1.35M	0.47%	50
2018 Q2	$9.22M	Buy	12,585 +4,284	+52%	+$4.94M	0.35%	66
2018 Q1	$13.2M	Buy	+8,301	New	+$10.7M	0.51%	44
2014 Q4	–	Sell	-22,320	Closed	-$4.04M	–	108
2014 Q3	$4.04M	Buy	+22,320	New	+$4.27M	0.19%	92

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Tekla Capital Management's NKTR Position: Q3 2021 in Review

Tekla Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 12,029 shares — an estimated $3.1M sold.

Tekla Capital Management first reported a position in NKTR in Q3 2014 and held it in 15 quarters. The position peaked at $13.2M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Tekla Capital Management reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 12,029 Nektar Therapeutics shares in Q3 2021, an estimated $3.1M.
Tekla Capital Management first reported a position in Nektar Therapeutics in Q3 2014 and held it in 15 quarters.
Tekla Capital Management's Nektar Therapeutics position peaked at $13.2M in Q1 2018.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.